Incyte Q4 Revenue Expected to Rise 14.8% to $1.35B With $1.95 EPS
Incyte reported Q3 revenue of $1.37 billion, beating forecasts by 8.4% and driving 20% year-on-year growth while topping EPS estimates. Analysts project Q4 revenue of $1.35 billion, a 14.8% increase, with adjusted EPS of $1.95, versus a two-year average top-line surprise of 3.4%.
1. Q3 Performance
Incyte delivered $1.37 billion in Q3 revenue, exceeding analyst expectations by 8.4% and marking 20% year-on-year growth. The company also beat consensus on adjusted EPS, reinforcing momentum from its flagship Jakafi franchise and newer assets.
2. Q4 Outlook
For the quarter ending March, analysts forecast 14.8% revenue growth to $1.35 billion, down from the prior quarter’s 16.3% pace. Adjusted earnings are estimated at $1.95 per share, reflecting expectations of continued pricing strength and volume gains.
3. Historical Surprise Record
Over the past two years, Incyte has missed revenue estimates only once and has beaten top-line forecasts by an average of 3.4%. This consistency underpins analyst confidence and supports Incyte’s current average price target of $104.23.
4. Peer and Sector Context
Among biotech peers, Regeneron reported 2.5% revenue growth, topping estimates by 2.7%, while Biogen saw a 7.1% decline, beating forecasts by 3.6%. The biotech group’s shares have slid 3.1% last month, whereas Incyte has advanced 1.9%, highlighting relative resilience.